Elizabeth R Woodruff

14PUBLICATIONS
59CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer cell biologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Aug 19, 2026
Inhibiting CXCR2 Remodels the Tumor Microenvironment and Blunts Tumor Progression and Dissemination of High-Grade Serous Carcinoma.

|Jan 24, 2026
Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor.

Tomomi M Yamamoto, Ritsuko Iwanaga, Elizabeth R Woodruff

|Dec 04, 2025
SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression.

Bradley R Corr, Elizabeth R Woodruff, Tomomi M Yamamoto

|Dec 03, 2024
Claudin-4 Stabilizes the Genome via Nuclear and Cell-Cycle Remodeling to Support Ovarian Cancer Cell Survival.

Fabian R Villagomez, Julie Lang, Daniel Nunez-Avellaneda

|Sep 16, 2024
Claudin-4 remodeling of nucleus-cell cycle crosstalk maintains ovarian tumor genome stability and drives resistance to genomic instability-inducing agents.

Fabian R Villagomez, Julie Lang, Daniel Nunez-Avellaneda

|Aug 13, 2024
EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell-Dependent Manner.

Lily L Nguyen, Zachary L Watson, Raquel Ortega

Pageof 3

Frequent Collaborators

14 joint publications

Benjamin G Bitler

8 joint publications

Tomomi M Yamamoto

6 joint publications

Ritsuko Iwanaga

6 joint publications

Kimberly R Jordan